Shares reach new low as Cardiac Science issues field correction
This article was originally published in Clinica
Cardiac Science’s share price took a battering this month, and reached an all-time low on Tuesday (November 24) after investors were hit not only with news of the company’s weak third-quarter results, but also that it has discovered defects in some its automated external defibrillators (AEDs). Shares fell to $2.10 each on November 24, their lowest valuation in the four years that the company has been listed on the Nasdaq.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals